Question:medium
A patient with HIV is recently diagnosed with multidrug-resistant tuberculosis. What is the appropriate regimen, and what should the patient be monitored for?
A patient with HIV is recently diagnosed with multidrug-resistant tuberculosis. What is the appropriate regimen, and what should the patient be monitored for?
Show Hint
MDR-TB regimen clue: BPaLM. HIV-TB treatment requires monitoring for IRIS.
Updated On: May 14, 2026
- BPaLM; monitor for immune reconstitution syndrome
- INH + Levofloxacin + Pyrazinamide + Ethambutol; monitor for hepatotoxicity
- INH + Levofloxacin + Streptomycin + Ethionamide; monitor for pyridoxine deficiency
- INH + Clarithromycin + Pyrazinamide + Ethambutol; monitor for optic neuritis
Show Solution
The Correct Option is A
Solution and Explanation
Step 1: Understanding the Question:
The question addresses the current standard of care for Multi-Drug Resistant TB (MDR-TB) in a co-infected HIV patient and the clinical monitoring required when starting therapy.
Step 2: Detailed Explanation:
MDR-TB Treatment: MDR-TB is defined by resistance to at least Isoniazid and Rifampicin. The current WHO-recommended shorter, all-oral regimen for most patients is the BPaLM regimen.
BPaLM Composition: It consists of Bedaquiline, Pretomanid, Linezolid (600 mg), and Moxifloxacin. This 6-month regimen has shown high efficacy and replaced older, longer, and more toxic injectable-based regimens.
Monitoring in HIV: When an HIV patient starts potent anti-TB therapy (or starts ART shortly after TB therapy), the improving immune system may "over-react" to the TB antigens present in the body.
IRIS: This is known as Immune Reconstitution Inflammatory Syndrome (IRIS). The patient may develop worsening fever, lymphadenopathy, or pulmonary infiltrates despite effective treatment. It is a critical clinical state to monitor for in HIV/TB co-infection.
Why others are incorrect: Options B, C, and D include Isoniazid (INH), which is ineffective by definition in MDR-TB.
Step 3: Final Answer:
The BPaLM regimen is the standard for MDR-TB, and patients with HIV must be closely monitored for the development of Immune Reconstitution Inflammatory Syndrome.
The question addresses the current standard of care for Multi-Drug Resistant TB (MDR-TB) in a co-infected HIV patient and the clinical monitoring required when starting therapy.
Step 2: Detailed Explanation:
MDR-TB Treatment: MDR-TB is defined by resistance to at least Isoniazid and Rifampicin. The current WHO-recommended shorter, all-oral regimen for most patients is the BPaLM regimen.
BPaLM Composition: It consists of Bedaquiline, Pretomanid, Linezolid (600 mg), and Moxifloxacin. This 6-month regimen has shown high efficacy and replaced older, longer, and more toxic injectable-based regimens.
Monitoring in HIV: When an HIV patient starts potent anti-TB therapy (or starts ART shortly after TB therapy), the improving immune system may "over-react" to the TB antigens present in the body.
IRIS: This is known as Immune Reconstitution Inflammatory Syndrome (IRIS). The patient may develop worsening fever, lymphadenopathy, or pulmonary infiltrates despite effective treatment. It is a critical clinical state to monitor for in HIV/TB co-infection.
Why others are incorrect: Options B, C, and D include Isoniazid (INH), which is ineffective by definition in MDR-TB.
Step 3: Final Answer:
The BPaLM regimen is the standard for MDR-TB, and patients with HIV must be closely monitored for the development of Immune Reconstitution Inflammatory Syndrome.
Was this answer helpful?
0
